Evidence map›Paper›PMID 33492420›Full record

ReviewDer Radiologe2021

[Systematic and quality-assured early diagnosis of sporadic breast cancer : Update on screening effects and scientific studies].

Walter Heindel, Karin Bock, Gerold Hecht, Sylvia Heywang-Köbrunner, Vanessa Kääb-Sanyal, Katja Siegmann-Luz, Stefanie Weigel

Open access · greenAbstract readReview
In one paragraph

Review in Der Radiologe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. [Structured screening for sporadic breast cancer].Radiologie (Heidelberg, Germany) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Walter HeindelKlinik für Radiologie und Referenzzentrum Mammographie Münster, Universität Münster (WWU) und Universitätsklinikum Münster (UKM), Albert-Schweitzer-Campus 1, Gebäude A1, 48149, Münster, Deutschland. heindel@uni-muenster.de.
Karin BockReferenzzentrum Mammographie Südwest, Bahnhofstraße 7, 35037, Marburg, Deutschland.
Gerold HechtReferenzzentrum Mammographie Nord, Heiligengeiststraße 28, 26121, Oldenburg, Deutschland.
Sylvia Heywang-KöbrunnerReferenzzentrum Mammographie München, Sonnenstraße 29, 80331, München, Deutschland.
Vanessa Kääb-SanyalGeschäftsstelle der Kooperationsgemeinschaft Mammographie, Goethestraße 85, 10623, Berlin, Deutschland.
Katja Siegmann-LuzReferenzzentrum Mammographie Berlin, Straße des 17. Juni 106-108, 10623, Berlin, Deutschland.
Stefanie WeigelKlinik für Radiologie und Referenzzentrum Mammographie Münster, Universität Münster (WWU) und Universitätsklinikum Münster (UKM), Albert-Schweitzer-Campus 1, Gebäude A1, 48149, Münster, Deutschland.
University Hospital Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA quality-assured mammography screening programme has been available since 2009, nationwide, to all women in Germany between the ages of 50 and 69. The programme is based on the European Guidelines. In this review article the authors summarize the current status of scientific assessments of this national early detection programme for breast cancer and provide an outlook regarding ongoing studies on effectiveness tests and further development.

resultsWe expect a decline in mortality rates relating to breast cancer as a result of successfully bringing diagnoses forward and a decrease in advanced breast cancer after a repeated screening. The extent will be shown in the current ZEBra study on mortality evaluation.

conclusionPotential for a further increase in the effectiveness of the systematic early detection of breast cancer can be identified in four areas: (1) More women should take advantage of the early detection opportunities offered by the medical insurance funds; so far, on average, only about 50% of the women between 50 and 69 who are entitled to a screening examination actually take part in the programme. (2) Entitlement to take part in the programme should be extended to women over 70. (3) The further development of digital mammography towards digital breast tomosynthesis promises to reduce the number of false positive recalls while at the same time increasing sensitivity. (4) There should be scientific studies relating to an extension of screening strategies for the small number of women in the entitlement range who have extremly dense breasts.

Indexed as

Breast NeoplasmsEarly Detection of CancerFemaleGermanyHumansMammographyProgram EvaluationQuality Assurance, Health CareAdvanced tumor stagesBreast cancerBreast cancer-related mortalityCancer registryQuality-assured mammography screening program

Identifiers

PMID33492420
PMCPMC7851039
OpenAlexW3122316679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.